×

Biotech and Pharmaceuticals Life Sciences

  • Health care stocks led the market higher, continuing their strong recent run, after the Senate released its proposal to revamp how Americans get medical care. Benchmark U.S. crude rose 28 cents, or 0.7 percent, to $42.81 per barrel. Brent crude, the international standard, added 45 cents, or 1 percent, to $45.27.

  • *Britain and Germany still ahead in the field. PARIS, June 15- France's corporate startup scene is gaining traction against the backdrop of booming investments by venture capital funds and high expectations for a business friendly government under new President Emmanuel Macron. The new president, who plans a raft of other measures start-u boosting measures...

  • *Britain and Germany still ahead in the field. PARIS, June 15- France's corporate startup scene is gaining traction against the backdrop of booming investments by venture capital funds and high expectations for a business friendly government under new President Emmanuel Macron. This taxpayer financing is 13 percent higher than the previous year and...

  • TORONTO _ Helix Biopharma Corp. on Tuesday reported a loss of $2.2 million in its fiscal third quarter. The Toronto- based company said it had a loss of 2 cents per share. Keywords: Helix Biopharma, Earnings Report.

  • WASHINGTON— A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions. Writing for the court, Justice Clarence Thomas said the law does not require companies making biosimilars to wait an extra six months after gaining Food and...

  • Trump may be the best thing that ever happened to the planet

    Trump's withdrawal from Paris agreement will motivate the private sector to take over where government is falling short.

  • JERUSALEM, June 7- Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study, setting it on course for U.S regulatory approval and launch in the second half of 2018.. Analysts have estimated it could generate at least $1 billion in sales annually. "Teva plans to submit a Biologics License...

  • DNA study maps genetic code to rethink human aging

    J. Craig Venter, Human Longevity Inc., explains how gathering massive amounts of data is helping to pioneer advances in genome studies and contribute to changing the way scientist think about health and aging.

  • CHICAGO, June 7- Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world's biggest annual oncology meeting. Investors had been closely watching the fortunes of CAR-T developers, including Kite Pharma Inc and...

  • Juno, which earlier this year gave up on developing CAR-T candidate JCAR015 for acute lymphoblastic leukemia after toxicities and patient deaths, presented early trial results at a meeting in Chicago of the American Society for Clinical Oncology for another candidate, JCAR017, as a treatment for non-Hodgkin lymphoma. "They needed to hit a grand slam home run...

  • Cramer Remix: What Chipotle’s past can tell you about Wells Fargo’s future

    Wells Fargo might not serve salsa, but Jim Cramer pointed out the two stocks have more in common than you might think.

  • *FDA backs 21 new drugs this year vs 22 for whole of 2016. LONDON, May 25- The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.

  • LONDON, May 22- AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Data from the 28- week Phase III clinical trial presented at the American Thoracic Society on Monday...

  • *Sees 2017 adjusted earnings of 4.4 bln- 4.6 bln euros. The family-controlled firm said on Thursday that sales of its performance materials would fall slightly in 2017, after adjusting for currency swings, having previously forecast growth for the division that is the world's leading supplier of liquid crystals ahead of Japan's JNC Corp and DIC Corp..

  • According to the FDA approval letter, the company has until December to submit the full trial data to the agency. Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer. In addition to Tecentriq's approval for bladder cancer patients whose disease has...

  • *Sees deal adding 30 cents to adjusted EPS in first year. May 15- Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in production and services for the biopharma industry. Thermo will also assume $2 billion in net debt, putting the cost of the...

  • LONDON, May 12- A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business. Shares in AstraZeneca extended gains to be up by 9.1 percent by mid-afternoon, the top FTSE 100 riser,...

  • LONDON, May 12- A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced the risk of death from advanced lung cancer, giving it a lead over rivals as it seeks to transform its oncology business. Shares in AstraZeneca were up 4.7 percent by 1000 GMT, the top FTSE 100 riser, and the company said it was in talks with the authorities over plans for...

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. "These are highly encouraging...

  • *Danish group looking for new drugs "adjacent" to diabetes. LONDON, May 11- Hit by pricing pressure in its core insulin business, Danish drugmaker Novo Nordisk is looking at new treatments for obesity- a major cause of diabetes- to help revive its growth. By contrast, Novo's newly approved anti-obesity injection Saxenda, launched in 2015 and containing the same GLP-1...